Table 2.
Meta-analysis of the association between MnSOD Val16Ala polymorphism and cancer risk.
| Variables | Number of studies | Sample size (case/controls) | Homozygous | Heterozygous | Recessive | Dominant | Allele comparison | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ala/Ala versus Val/Val | Val/Ala versus Val/Val | Ala/Ala versus (Val/Val + Val/Ala) | (Ala/Ala + Val/Ala) versus Val/Val | Ala versus Val | ||||||||
| OR (95% CI) | P het | OR (95% CI) | P het | OR (95% CI) | P het | OR (95% CI) | P het | OR (95% CI) | P het | |||
| All | 88 | 33,098/37,831 | 1.09 (1.00–1.19) | <0.001 | 1.07 (1.02–1.12) | 0.001 | 1.05 (0.99–1.11) | <0.001 | 1.08 (1.02–1.14) | <0.001 | 1.06 (1.02–1.11) | <0.001 |
| Cancer type | ||||||||||||
| Breast | 24 | 12,479/12,603 | 1.03 (0.95–1.13) | 0.276 | 1.02 (0.96–1.09) | 0.302 | 1.02 (0.94–1.10) | 0.157 | 1.01 (0.94–1.09) | 0.066 | 1.02 (0.97–1.06) | 0.226 |
| Prostate | 17 | 7101/9146 | 1.04 (0.87–1.24) | 0.002 | 1.14 (1.05–1.24) | 0.765 | 1.03 (0.94–1.14) | 0.225 | 1.14 (1.05–1.23) | 0.552 | 1.07 (1.00–1.15) | 0.106 |
| Lung | 6 | 2021/2347 | 1.13 (0.63–2.04) | 0.019 | 1.05 (0.76–1.46) | 0.016 | 0.91 (0.72–1.14) | 0.313 | 1.02 (0.78–1.32) | 0.021 | 0.98 (0.80–1.21) | 0.039 |
| Bladder | 6 | 1271/1270 | 0.66 (0.39–1.13) | 0.002 | 0.91 (0.68–1.23) | 0.049 | 1.01 (0.83–1.24) | 0.520 | 0.93 (0.68–1.26) | 0.021 | 0.97 (0.80–1.19) | 0.033 |
| Pancreatic | 6 | 1422/2043 | 1.01 (0.59–1.73) | 0.007 | 1.07 (0.77–1.49) | 0.032 | 1.08 (0.77–1.50) | 0.020 | 1.04 (0.70–1.55) | 0.002 | 1.04 (0.76–1.43) | <0.001 |
| CRC | 5 | 2258/2180 | 1.02 (0.86–1.20) | 0.856 | 1.04 (0.90–1.20) | 0.733 | 0.99 (0.86–1.13) | 0.967 | 1.03 (0.90–1.18) | 0.733 | 1.01 (0.93–1.09) | 0.863 |
| Ovarian | 3 | 716,1358 | 1.10 (0.85–1.42) | 0.839 | 1.15 (0.92–1.45) | 0.773 | 1.00 (0.81–1.23) | 0.973 | 1.13 (0.92–1.40) | 0.748 | 1.05 (0.92–1.19) | 0.836 |
| HCC | 3 | 593/759 | 1.92 (0.85–4.36) | 0.050 | 1.15 (0.66–2.00) | 0.055 | 1.70 (0.97–2.97) | 0.162 | 1.36 (0.67–2.76) | 0.005 | 1.34 (0.76–2.35) | 0.001 |
| NHL | 3 | 2123/2479 | 1.96 (0.96–4.00) | <0.001 | 1.03 (0.89–1.19) | 0.551 | 1.08 (0.94–1.24) | 0.357 | 1.05 (0.92–1.20) | 0.831 | 1.05 (0.96–1.14) | 0.849 |
| Other cancers | 15 | 3114/3646 | 1.79 (1.18–2.70) | <0.001 | 1.25 (1.05–1.49) | 0.058 | 1.54 (1.07–2.20) | <0.001 | 1.32 (1.08–1.61) | 0.001 | 1.32 (1.08–1.61) | <0.001 |
| Ethnicity | ||||||||||||
| Asian | 18 | 5092/5748 | 1.82 (1.15–2.88) | 0.020 | 1.10 (0.94–1.30) | 0.001 | 1.76 (1.16–2.68) | 0.065 | 1.08 (0.91–1.29) | <0.001 | 1.16 (0.96–1.40) | <0.001 |
| Caucasian | 56 | 23,738/26,121 | 1.03 (0.94–1.12) | <0.001 | 1.08 (1.03–1.13) | 0.208 | 1.02 (0.96–1.08) | 0.005 | 1.08 (1.02–1.14) | 0.011 | 1.04 (1.00–1.09) | <0.001 |
| African | 7 | 1530/1758 | 1.58 (0.85–2.93) | <0.001 | 0.95 (0.80–1.12) | 0.442 | 0.98 (0.79–1.21) | 0.314 | 0.99 (0.81–1.20) | 0.289 | 1.01 (0.87–1.17) | 0.168 |
| Mixed | 7 | 2738/4204 | 1.11 (0.88–1.42) | 0.141 | 0.98 (0.81–1.19) | 0.196 | 1.12 (0.97–1.31) | 0.187 | 1.02 (0.85–1.23) | 0.177 | 1.06 (0.94–1.21) | 0.107 |
| Source of control | ||||||||||||
| PB | 48 | 23,004/27,193 | 1.10 (1.01–1.19) | <0.001 | 1.07 (1.02–1.12) | 0.263 | 1.02 (0.97–1.08) | 0.071 | 1.07 (1.02–1.13) | 0.071 | 1.04 (1.00–1.08) | 0.006 |
| HB | 40 | 10,094/10,638 | 1.09 (0.88–1.35) | <0.001 | 1.08 (0.98–1.20) | 0.003 | 1.16 (1.01–1.34) | <0.001 | 1.10 (0.98–1.23) | <0.001 | 1.13 (1.03–1.24) | <0.001 |
| Quality score | ||||||||||||
| Low | 39 | 7625/7608 | 1.15 (0.90–1.46) | <0.001 | 1.09 (0.98–1.22) | 0.025 | 1.13 (0.99–1.29) | 0.015 | 1.11 (0.98–1.26) | <0.001 | 1.12 (1.02–1.23) | <0.001 |
| High | 49 | 25,473/30,223 | 1.08 (1.00–1.17) | 0.001 | 1.07 (1.02–1.13) | 0.067 | 1.03 (0.97–1.09) | 0.002 | 1.07 (1.02–1.14) | 0.002 | 1.04 (1.00–1.09) | <0.001 |
Het: heterogeneity; CRC: colorectal cancer; HCC: hepatocellular carcinoma; NHL: non-Hodgkin's lymphoma; PB: population-based; HB: hospital-based.